Stryker Co. (NYSE:SYK) Shares Acquired by O Shaughnessy Asset Management LLC

O Shaughnessy Asset Management LLC lifted its position in Stryker Co. (NYSE:SYK - Free Report) by 8.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 40,259 shares of the medical technology company's stock after purchasing an additional 3,076 shares during the quarter. O Shaughnessy Asset Management LLC's holdings in Stryker were worth $14,495,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Dynamic Technology Lab Private Ltd acquired a new stake in Stryker during the 3rd quarter worth $317,000. Townsquare Capital LLC raised its holdings in shares of Stryker by 11.9% in the third quarter. Townsquare Capital LLC now owns 7,468 shares of the medical technology company's stock valued at $2,698,000 after buying an additional 792 shares during the last quarter. CreativeOne Wealth LLC boosted its stake in shares of Stryker by 46.8% during the third quarter. CreativeOne Wealth LLC now owns 2,078 shares of the medical technology company's stock worth $751,000 after buying an additional 662 shares during the period. Rockefeller Capital Management L.P. grew its holdings in shares of Stryker by 6.6% during the third quarter. Rockefeller Capital Management L.P. now owns 54,564 shares of the medical technology company's stock worth $19,712,000 after buying an additional 3,358 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec raised its stake in Stryker by 18.8% during the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 255,436 shares of the medical technology company's stock valued at $92,279,000 after acquiring an additional 40,411 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Royal Bank of Canada boosted their target price on Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a report on Wednesday, January 29th. StockNews.com cut shares of Stryker from a "buy" rating to a "hold" rating in a research note on Thursday, March 6th. Stifel Nicolaus raised their target price on shares of Stryker from $400.00 to $440.00 and gave the stock a "buy" rating in a research note on Wednesday, January 29th. Canaccord Genuity Group lifted their target price on shares of Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a report on Wednesday, January 29th. Finally, Citigroup restated a "buy" rating and issued a $450.00 price objective on shares of Stryker in a research report on Wednesday, February 26th. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $421.90.

Stryker Price Performance

SYK stock traded down $22.01 on Friday, reaching $346.14. The company had a trading volume of 3,956,734 shares, compared to its average volume of 1,318,651. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The company's fifty day moving average is $381.69 and its 200 day moving average is $374.23. The company has a market cap of $132.12 billion, a P/E ratio of 44.61, a PEG ratio of 2.93 and a beta of 0.95. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the firm posted $3.46 earnings per share. On average, research analysts forecast that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.97%. The ex-dividend date of this dividend is Monday, March 31st. Stryker's payout ratio is 43.30%.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the firm's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares of the company's stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.50% of the stock is owned by company insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.